drug resistance – Page 2

John Perfect Shares Insights on Infectious Diseases, Antifungal Therapy, and Drug Resistance

mycolabadmin

This interview with Dr. John Perfect, a leading expert in fungal infections, discusses how antifungal treatments have evolved over his 48-year career. He explains that while fungal resistance is a concern, it’s less problematic than bacterial antibiotic resistance because fungi don’t spread resistance through plasmids. Dr. Perfect emphasizes the importance of newer, faster-acting antifungal drugs and combining drug therapy with immune system support to better treat serious fungal infections like cryptococcal meningitis and candidemia.

Healthcare-associated fungal infections and emerging pathogens during the COVID-19 pandemic

mycolabadmin

During the COVID-19 pandemic, fungal infections became a serious complication in hospitalized patients, especially those receiving steroids and other immune-suppressing treatments. Common fungal pathogens like Candida and Aspergillus caused dangerous coinfections, with infection rates varying significantly by region. Current antifungal medications have significant limitations including toxicity and resistance, highlighting the urgent need for new and safer antifungal treatments.

John Perfect Shares Insights on Infectious Diseases, Antifungal Therapy, and Drug Resistance

mycolabadmin

Dr. John Perfect, a leading expert in fungal infections, shares his 48 years of experience studying infectious diseases, particularly focusing on Cryptococcus and candida infections. He discusses how antifungal medications have evolved from highly toxic drugs to more effective treatments, while emphasizing the need for faster-acting drugs that require shorter treatment periods. The interview covers emerging diagnostic tools using molecular methods, the promise of combining drugs with immune-boosting therapies, and the importance of understanding how fungi survive in the human body to develop better treatments.

Antifungal Potential of Streptomyces-Derived Metabolites Against Fluconazole-Resistant Oral Candida albicans: In vitro Evaluation and Mechanistic Insights

mycolabadmin

Researchers studied a type of soil bacteria called Streptomyces that produces natural compounds with strong antifungal properties. These compounds effectively killed drug-resistant Candida fungal infections that commonly affect cancer patients undergoing radiation therapy. The bacterial extract worked by damaging fungal cell membranes and blocking biofilm formation, which are protective structures the fungus uses to survive. While the results are promising for treating stubborn fungal infections, more research is needed to ensure safety for human patients.

Phytochemicals as promising agents in Axl-targeted cancer treatment

mycolabadmin

This review examines natural plant compounds that can block Axl, a protein that helps cancer cells survive and spread. Scientists found that compounds from common foods like apples, grapes, green tea, ginger, and chamomile can reduce Axl levels and kill cancer cells. These natural compounds work through different mechanisms and show promise for treating various cancers, including those resistant to standard chemotherapy drugs.

Synergistic potential and apoptosis induction of Bunium persicum essential oil and its pure components, cuminaldehyde and γ-terpinene, in combination with fluconazole on Candida albicans isolates: in vitro and in silico evaluation

mycolabadmin

Researchers studied how an essential oil from black cumin seeds (Bunium persicum) and two of its key active components could work together with the antifungal drug fluconazole to fight Candida albicans infections, including drug-resistant strains. Using laboratory tests and computer modeling, they found that cuminaldehyde, one of the main components, was particularly effective when combined with fluconazole, killing yeast cells through multiple mechanisms. This suggests that natural plant compounds could be valuable partners with conventional antifungal medications to overcome drug resistance.

The endophytic fungus Cosmosporella sp. VM-42 from Vinca minor is a source of bioactive compounds with potent activity against drug-resistant bacteria

mycolabadmin

Scientists discovered a fungus living inside a medicinal plant called Vinca minor that produces compounds capable of killing drug-resistant bacteria like MRSA. They isolated the main active compound, nectriapyrone, and found it effectively stops the growth of these dangerous bacteria in laboratory tests. The fungus appears to be a promising source of new antibacterial drugs that could help combat the growing problem of antibiotic-resistant infections.

Progress of Antimicrobial Mechanisms of Stilbenoids

mycolabadmin

Stilbenoids are natural compounds found in plants that can fight harmful bacteria and fungi in multiple ways. Unlike traditional antibiotics that only kill microbes, stilbenoids can also prevent infections by disrupting biofilm formation and weakening pathogen virulence. These compounds show promise in combating drug-resistant infections without promoting further resistance development, making them valuable candidates for new antibiotic medicines.

Synergistic potential and apoptosis induction of Bunium persicum essential oil and its pure components, cuminaldehyde and γ-terpinene, in combination with fluconazole on Candida albicans isolates: in vitro and in silico evaluation

mycolabadmin

Researchers tested how Bunium persicum essential oil and its components work alongside the antifungal drug fluconazole against Candida albicans infections. Cuminaldehyde, a major component of the oil, showed the strongest effects when combined with fluconazole, making infection-causing cells die faster than each substance alone. This combination approach could help overcome drug-resistant fungal infections and offers a promising natural alternative to synthetic drugs alone.

A case report of disseminated histoplasmosis not responding to primary treatment by itraconazole

mycolabadmin

A healthy 28-year-old woman developed a serious fungal infection caused by Histoplasma capsulatum after dental surgery. The standard antifungal medication (itraconazole) did not work for her, even at high doses. Doctors successfully treated her with a more powerful antifungal drug called liposomal amphotericin B, which cleared the infection completely. This case shows the importance of adjusting treatment when patients don’t respond to initial therapy.

Research Topic: drug resistance